-
Mashup Score: 3CCF - CHILDREN'S CARDIOMYOPATHY FOUNDATION - 6 month(s) ago
— —– ——— —–, —– — —- —— ——- ———– —– — —- — ——— —–. — —– ——— —–, —– — —- —— ——- ———– —– — —- — ——— —–. — —– ——— —–, —– — —- —— ——- ———– —– — —- — ——— —–. — —– ——— —–, —– — —- —— ——- ———– —– — —- — ——— —–. — —– ——— —–, —– — —- —— ——- ———– —– — —- — ——— —–.
Source: www.childrenscardiomyopathy.orgCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 3FDA Approves Acoramidis (Attruby) for ATTR-CM - 8 month(s) ago
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
🚨 FDA Approval Alert! 🚨 @BridgeBioPharma has announced the approval of acoramidis for the treatment of adults with ATTR-CM. Learn more: https://t.co/PVtcamqUK0 #Cardiomyopathy https://t.co/2abWGtuglD
-
-
Mashup Score: 12Ahmad Masri, MD, MS: 2024 Update on Development and Future of Cardiac Myosin Inhibitor Class - 1 year(s) ago
Ahmad Masri, MD, MS, provides an update on the the development of the cardiac myosin inhibitor class and offers perspective on what the future might hold for the class beyond cardiomyopathy.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
In this interview, @MasriAhmadMD provides an update on the the development of the cardiac myosin inhibitor class and offers perspective on what the future might hold for the class beyond #cardiomyopathy. https://t.co/Vcx4YH3d7D https://t.co/7ISqkfiiuX
-
-
Mashup Score: 5
Topics Include: – Genetics 101 – Gene Therapy Basics – Clinical Trials for Gene Therapy – Tenaya and Gene Therapy Advancement – Live Q&A Guest Speakers: Wendy Borsari, Senior Manager Patient Advocacy – Tenaya Therapeutics Jeff Haroldson, Sr. Director Medical Affairs – Tenaya Therapeutics We hope you can join us for this fascinating webinar!
Source: us06web.zoom.usCategories: General Medicine News, Rare DiseaseTweet-
Team Titin announces a webinar hosted by the Dilated Cardiomyopathy Foundation "Understanding Cardiomyopathy Genetic Therapies - Our Hope for the Future." Learn about genetics, gene therapy, and #cardiomyopathy on December 13th by registering here: https://t.co/htxvAa8nnQ
-
-
Mashup Score: 59
Supriya Shore, MD
Source: www.acc.orgCategories: General Medicine News, Cardiology News and JournTweet-
🔑 HCM is caused by cardiac sarcomere dysfunction causing excess myosin-actin cross-bridging and increased calcium sensitivity. Read more key points from a state-of-the-art review on mavacamten for obstructive HCM: https://t.co/EgG1hIMI4U #Cardiomyopathy
-
-
Mashup Score: 0Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis - 2 year(s) ago
Our findings suggested that there was no significant deterioration in LVEF in the patients with wild-type ATTR after tafamidis treatment. In addition, tafamidis treatment was associated with a low risk of all-cause death and adverse cardiovascular events.
Source: www.thelancet.comCategories: General Medicine News, General Journals & SocietTweet-
Tafamidis treatment in patients with transthyretin amyloid #cardiomyopathy: a systematic review and meta-analysis This work suggested that there was no significant deterioration in LVEF in the patients with wild-type ATTR after tafamidis treatment https://t.co/7TCrdh77CO https://t.co/qDLpSOdevp
-
-
Mashup Score: 0
Ahmad Masri, MD, MS, discusses long-term data from the open-label extension period of the phase 2 AG10-201 trial examining acoramidis in patients with ATTR-CM.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
At #HFSA2023, we sat down with @MasriAhmad to learn more about the ACACIA-HCM trial of aficamten in nHCM. Learn more: https://t.co/3SGsKr0dnr #Cardiology #Cardiomyopathy https://t.co/HKhR3377Bk
-
-
Mashup Score: 0Despite panel support, FDA rejects patisiran for ATTR amyloidosis with cardiomyopathy - 2 year(s) ago
The FDA rejected a supplemental new drug application for patisiran to treat cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness.In a complete response letter issued by FDA, the agency stated that it did not identify any clinical safety, study conduct, drug quality or manufacturing issues for
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: @US_FDA rejected a supplemental new drug application for #patisiran to treat #cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness #Cardiotwitter https://t.co/Si0DgSOeQB
-
-
Mashup Score: 0FDA Issues CRL for Patisiran in Treatment of ATTR Cardiomyopathy - 2 year(s) ago
Announced on October 9, the decision to issue a CRL is based on the FDA’s belief the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
ICYMI: Earlier this week, the FDA issued a CRL for patisiran in the treatment of ATTR cardiomyopathy. Learn more: https://t.co/gySrqLHzhf #Cardiomyopathy https://t.co/plnV9kQSvC
-
-
Mashup Score: 0Despite panel support, FDA rejects patisiran for ATTR amyloidosis with cardiomyopathy - 2 year(s) ago
The FDA rejected a supplemental new drug application for patisiran to treat cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness.In a complete response letter issued by FDA, the agency stated that it did not identify any clinical safety, study conduct, drug quality or manufacturing issues for
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: @US_FDA rejected a supplemental new drug application for #patisiran to treat #cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness #Cardiotwitter https://t.co/Si0DgSOeQB
-
We're happy to welcome our newest NORD Member Organization, Children's Cardiomyopathy Foundation, @CCFheartkids! Learn how they're advancing care and support for families affected by pediatric #cardiomyopathy and other heart-related rare diseases: https://t.co/E7Ya1MkfTB… https://t.co/gwGxMBqgym https://t.co/cp6d7ErcEJ